Elicio Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
ELTX$1.65+8.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $12,894 | $6,156 |
| Restricted cash, current | 722 | 1,641 |
| Prepaid expenses and other current assets | 2,732 | 2,920 |
| Total current assets | 16,348 | 10,717 |
| Property and equipment, net | 717 | 1,147 |
| Operating lease, right-of-use assets | 6,563 | 7,350 |
| Restricted cash, noncurrent | 685 | 617 |
| Other long-term prepaid assets | 2,833 | 2,833 |
| Total assets | $27,146 | $22,664 |
| Liabilities, convertible preferred stock, and stockholders’ equity (deficit) | ||
| Current liabilities | ||
| Accounts payable | $4,369 | $2,805 |
| Accrued expenses | 3,757 | 1,935 |
| Deferred research obligation | 694 | 1,436 |
| Operating lease liability, current | 910 | 692 |
| Unvested option exercise liability, current | 25 | — |
| Warrant liability | 11 | — |
| Total current liabilities | 9,766 | 6,868 |
| Operating lease liability, noncurrent | 6,007 | 6,789 |
| Unvested option exercise liability, noncurrent | — | 92 |
| Total liabilities | 15,773 | 13,749 |
| Convertible preferred stock: | ||
| Series A convertible preferred stock, $0.06 par value:no shares and 132,387 shares authorized, issued and outstanding at December 31, 2023 and 2022, respectively | — | 7,495 |
| Series B convertible preferred stock, $0.06 par value:no shares and 1,927,375 shares authorized, issued and outstanding at December 31, 2023 and 2022, respectively | — | 62,944 |
| Series C convertible preferred stock, $0.06 par value:no shares and 4,888,798 shares authorized at December 31, 2023 and 2022, respectively; no shares and 2,938,158 shares issued and outstanding at December 31, 2023 and 2022, respectively | — | 40,621 |
| Total convertible preferred stock | — | 111,060 |
| Stockholders' equity (deficit): | ||
| Common stock, $0.01 par value; 300,000,000 shares authorized at December 31, 2023 and 2022, respectively; 9,618,178 and 320,281 shares issued at December 31, 2023 and 2022, respectively; 9,603,723 and 320,281 shares outstanding as of December 31, 2023 and 2022, respectively | 96 | 3 |
| Treasury stock, at cost, 14,455 and no shares outstanding as of December 31, 2023 and 2022, respectively | (150) | — |
| Additional paid-in capital | 153,827 | 4,860 |
| Accumulated other comprehensive loss | (197) | — |
| Accumulated deficit | (142,203) | (107,008) |
| Total stockholders' equity (deficit) | 11,373 | (102,145) |
| Total liabilities, convertible preferred stock, and stockholders’ equity (deficit) | $27,146 | $22,664 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.